Does TOFACITINIB Cause Upper respiratory tract infection? 1,805 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 1,805 reports of Upper respiratory tract infection have been filed in association with TOFACITINIB (XELJANZ XR). This represents 1.2% of all adverse event reports for TOFACITINIB.
1,805
Reports of Upper respiratory tract infection with TOFACITINIB
1.2%
of all TOFACITINIB reports
247
Deaths
288
Hospitalizations
How Dangerous Is Upper respiratory tract infection From TOFACITINIB?
Of the 1,805 reports, 247 (13.7%) resulted in death, 288 (16.0%) required hospitalization, and 105 (5.8%) were considered life-threatening.
Is Upper respiratory tract infection Listed in the Official Label?
Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for TOFACITINIB.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Upper respiratory tract infection?
ADALIMUMAB (3,306)
ETANERCEPT (2,948)
RITUXIMAB (1,713)
ABATACEPT (1,623)
METHOTREXATE (1,576)
TOCILIZUMAB (1,455)
APREMILAST (1,437)
PREDNISONE (1,354)
SECUKINUMAB (1,339)
LENALIDOMIDE (1,334)
Which TOFACITINIB Alternatives Have Lower Upper respiratory tract infection Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN